Renewing the Fight Against Bacteria

In the 1940s, the mass production of penicillin led to a sensational reduction in illness and death from bacterial disease. A resulting golden era of bacterial research emerged with new classes of antibiotics, and by 1969, US Surgeon General William H. Stewart told Congress: "The time has come to close the book on infectious disease." As a result, fewer new students specialized in bacterial physiology, and federal funders shifted their focus to more immediately pressing diseases, as did many pha

Written byJennifer Fisher Wilson
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

As a result, fewer new students specialized in bacterial physiology, and federal funders shifted their focus to more immediately pressing diseases, as did many pharmaceutical companies. But while everyone forgot about the bacteria, the bacteria didn't completely abandon their unwilling hosts.

Today, nearly all strains of Staphylococcus aureus, an organism that causes skin, bone, lung, and bloodstream infections, now resist penicillin. Many do the same to methicillin, and some even resist vancomycin, long considered the only uniformly effective drug for methicillin-resistant S. aureus, according to the Centers for Diseases Control and Prevention (CDC). The agency also estimates that 30% of Streptococcus pneumoniae-caused pneumonia, meningitis, and ear infections no longer respond to penicillin. In fact, about 70% of bacteria found in hospitals resist at least one of the drugs most commonly used to treat infection, according to CDC estimates. Antibiotics resistance continues to increase; much of it occurs from misuse. Physicians ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies